Literature DB >> 7931471

Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil.

G J Peters1, C L van der Wilt, C J van Groeningen, K Smid, S Meijer, H M Pinedo.   

Abstract

PURPOSE: To determine the time-dependence of fluorouracil (5FU)-induced thymidylate synthase (TS) inhibition in colon cancer patients, the effect of leucovorin (LV), and the relation to response. PATIENTS AND METHODS: A 5FU injection (500 mg/m2) was given to 47 patients with advanced colorectal cancer; tumor biopsy specimens were obtained 1 to 72 hours after laparotomy. Eleven patients received LV (2-hour infusion of 500 mg/m2) with 5FU midinfusion; biopsies were obtained after 45 hours. TS inhibition was evaluated by comparing the number of total and free 5-fluoro-2'-deoxy-uridine-5'- monophosphate (UMP) (FdUMP) binding sites and the total and residual catalytic activity of TS.
RESULTS: The total catalytic TS activity varied from 0 to 621 pmol/h/mg protein and the total number of FdUMP binding sites varied from 0 to 976 fmol/mg protein. The residual catalytic TS activity after 2, 23, and 45 hours was 41%, 65%, and 74% of the total catalytic activity; the number of free FdUMP binding sites was 12%, 27%, and 49% of the total number, respectively. LV enhanced TS inhibition after 45 hours; the residual catalytic activity decreased from 74% to 49%, and the number of free FdUMP binding sites from 49% to 24%. Eleven of 19 patients treated with hepatic arterial infusion of 5FU had a partial response (PR). In the nonresponding patients, total TS activity was significantly higher (P < .05) than in responding patients. A high TS activity with a poor inhibition correlated with no response.
CONCLUSION: Residual and total TS activity are predictive for response to 5FU. The findings may be applicable for treatment of patients with advanced disease and TS should be evaluated as a prognostic factor in adjuvant chemotherapy studies.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7931471     DOI: 10.1200/JCO.1994.12.10.2035

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  29 in total

1.  Comparison of adjuvant FOLFOX4 chemotherapy and oral UFUR/LV following adjuvant FOLFOX4 chemotherapy in patients with stage III colon cancer subsequent to radical resection.

Authors:  Ming-Yii Huang; Chun-Ming Huang; Hsiang-Lin Tsai; Ching-Wen Huang; Hui-Min Hsieh; Yung-Sung Yeh; Jeng-Yih Wu; Wen-Ming Wang; Jaw-Yuan Wang
Journal:  Oncol Lett       Date:  2017-09-26       Impact factor: 2.967

2.  Antisense-induced down-regulation of thymidylate synthase and enhanced cytotoxicity of 5-FUdR in 5-FUdR-resistant HeLa cells.

Authors:  P J Ferguson; J M DeMoor; M D Vincent; J Koropatnick
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

Review 3.  Modulation of 5-fluorouracil by interferon: a review of potential cellular targets.

Authors:  R Horowitz; E L Schwartz; S Wadler
Journal:  Med Oncol       Date:  1995-03       Impact factor: 3.064

4.  Antisense down-regulation of thymidylate synthase to suppress growth and enhance cytotoxicity of 5-FUdR, 5-FU and Tomudex in HeLa cells.

Authors:  P J Ferguson; O Collins; N M Dean; J DeMoor; C S Li; M D Vincent; J Koropatnick
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

5.  Bcl-2 expression significantly correlates with thymidylate synthase expression in colorectal cancer patients.

Authors:  Riyad Bendardaf; Raija Ristamaki; Kari Syrjanen; Seppo Pyrhonen
Journal:  World J Gastroenterol       Date:  2008-10-28       Impact factor: 5.742

6.  Successful treatment of advanced gallbladder cancer with an anticancer drug S-1: assessment based on intratumoral gene.

Authors:  Kumiko Kitajima; Susumu Kobayashi; Hiroaki Shiba; Tadashi Uwagawa; Yuichi Ishida; Keisuke Aiba; Makio Kawakami; Katsuhiko Yanaga
Journal:  Int J Clin Oncol       Date:  2008-12-18       Impact factor: 3.402

Review 7.  Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil. Is it time to move forward?

Authors:  Shayna L Showalter; Timothy N Showalter; Agnes Witkiewicz; Robert Havens; Eugene P Kennedy; Tomas Hucl; Scott E Kern; Charles J Yeo; Jonathan R Brody
Journal:  Cancer Biol Ther       Date:  2008-04-21       Impact factor: 4.742

Review 8.  Standing the test of time: targeting thymidylate biosynthesis in cancer therapy.

Authors:  Peter M Wilson; Peter V Danenberg; Patrick G Johnston; Heinz-Josef Lenz; Robert D Ladner
Journal:  Nat Rev Clin Oncol       Date:  2014-04-15       Impact factor: 66.675

Review 9.  Molecular predictors of treatment and outcome in colorectal cancer.

Authors:  Syma Iqbal; Heinz-Josef Lenz
Journal:  Curr Gastroenterol Rep       Date:  2003-10

10.  XIII International Charles Heidelberger Symposium and 50 Years of Fluoropyrimidines in Cancer Therapy Held on september 6 to 8, 2007 at New York University Cancer Institute, Smilow Conference Center.

Authors:  Franco M Muggia; Godefridus J Peters; Joseph R Landolph
Journal:  Mol Cancer Ther       Date:  2009-05-05       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.